Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocCheck AGXTER:AJ91 71 EBITDA Margin % is 21.22% as of Dec. 2025, which is 8% above its 10-year median of 19.65. GuruFocus rates XTER:AJ91 with a GF Score™ of 71/100 and a GF Value™ of €9.52 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 664 Healthcare Providers & Services companies, DocCheck AG ranks better than 76.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. DocCheck AG's EBITDA for the
six
months ended in Dec. 2025 was €6.11 Mil. DocCheck AG's Revenue for the
six
months ended in Dec. 2025 was €28.77 Mil. Therefore, DocCheck AG's EBITDA margin for the quarter that ended in Dec. 2025 was 21.22%.
DocCheck AG (XTER:AJ91) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DocCheck AG EBITDA Margin % Related Terms
DocCheck AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for DocCheck AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AJ91 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, DocCheck AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DocCheck AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DocCheck AG (XTER:AJ91) has a EBITDA Margin % of 21.22% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DocCheck AG and its competitors. This is near median its historical median of 19.65. Over the past decade, DocCheck AG's EBITDA Margin % has ranged from 16.29 to 25.20. According to the industry distribution chart, DocCheck AG ranks #155 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 23.3%.
Is DocCheck AG's EBITDA Margin % too high?
DocCheck AG's current EBITDA Margin % of 21.22% is near median its 10-year median of 19.65. Over the past 10 years, this metric has ranged from a low of 16.29 to a high of 25.20. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. DocCheck AG's value of 21.22% is 107.8% above this industry median. Based on the distribution chart, DocCheck AG ranks #155 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DocCheck AG has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DocCheck AG ranks #155 out of 664 companies for EBITDA Margin %. This places DocCheck AG in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. DocCheck AG's value of 21.22% is 107.8% above this benchmark. Historically, DocCheck AG's own EBITDA Margin % has ranged from 16.29 to 25.20 over the past decade. While the company's 10-year median is 19.65 vs. the industry median of 10.21, DocCheck AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current EBITDA Margin % of 21.22% is 107.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DocCheck AG and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current EBITDA Margin % is 21.22%, which is near median its own 10-year median of 19.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
Based on GuruFocus' analysis, DocCheck AG (XTER:AJ91) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.52, compared to a current price of €11.80 — trading 23.9% above its estimated fair value. The current EBITDA Margin % is 21.22%, which is near median its 10-year median of 19.65 and 107.8% above the Healthcare Providers & Services industry median of 10.21. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DocCheck AG (XTER:AJ91), the current EBITDA Margin % is 21.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (XTER:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €11.80 is trading 23.9% above its estimated GF Value™ of €9.52.
GuruFocus considers DocCheck AG to be Modestly Overvalued.
Key valuation signals for XTER:AJ91:
EBITDA Margin %: 21.22% (near median its 10-year median of 19.65)
GF Value™: €9.52 vs. price of €11.80 (23.9% above fair value)
Industry Position: 107.8% above the Healthcare Providers & Services median (#155 of 664)
No single metric tells the full story. See the XTER:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for XTER:AJ91
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AJ91 has been successfully added to your 
